Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates...

Full description

Bibliographic Details
Main Authors: Farah M. Shurrab, Duaa W. Al-Sadeq, Haissam Abou-Saleh, Nader Al-Dewik, Amira E. Elsharafi, Fatima M. Hamaydeh, Bushra Y. Abo Halawa, Tala M. Jamaleddin, Huda M. Abdul Hameed, Parveen B. Nizamuddin, Fathima Humaira Amanullah, Hanin I. Daas, Laith J. Abu-Raddad, Gheyath K. Nasrallah
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Vaccines
Subjects:
neutralizing antibodies
Pfizer-BNT162b2
Moderna-mRNA-1273
SARS-CoV-2
vaccine
Online Access:https://www.mdpi.com/2076-393X/10/2/191

Similar Items

Similar Items